Evidence map›Paper›PMID 25192687›Full record

ArticleInternational orthopaedics2014

Evaluation of fibrin-based gene-activated matrices for BMP2/7 plasmid codelivery in a rat nonunion model.

Martin Kaipel, Sebastian Schützenberger, Anna T Hofmann, James Ferguson, Thomas Nau, Heinz Redl, Georg A Feichtinger

Abstract read
PubMed Publisher
In one paragraph

Article in International orthopaedics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Rapid Magneto-Sonoporation of Adipose-Derived Cells.Materials (Basel, Switzerland) · 2021
    Article
  6. Article
  7. Article
  8. Gene therapy for bone engineering.Frontiers in bioengineering and biotechnology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Martin KaipelOrthopaedic Department, Barmherzige Brüder Hospital, Johannes von Gott-Platz 1/A-7000, Eisenstadt, Austria, martin.kaipel@bbeisen.at.
Sebastian Schützenberger
Anna T Hofmann
James Ferguson
Thomas Nau
Heinz Redl
Georg A Feichtinger
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTreatment of large-segmental bone defects still is a challenge in clinical routine. Application of gene-activated matrices (GAMs) based on fibrin, bone morphogenic protein (BMP) 2/7 plasmids and nonviral transfection reagents (cationic polymers) could be an innovative treatment strategy to overcome this problem. The aim of this study was to determine the therapeutic efficacy of fibrin GAMs with or without additional transfection reagents for BMP2 and 7 plasmid codelivery in a femur nonunion rat model.

methodsIn this experimental study, a critical-sized femoral defect was created in 27 rats. At four weeks after the surgery, animals were separated into four groups and underwent a second operation. Fibrin clots containing BMP2/7 plasmids with and without cationic polymer were implanted into the femoral defect. Fibrin clots containing recombinant human (rh) BMP2 served as positive and clots without supplement as negative controls.

resultsAt eight weeks, animals that received GAMs containing the cationic polymer and BMP2/7 plasmids showed decreased bone volume compared with animals treated with GAMs and BMP2/7 only. Application of BMP2/7 plasmids in fibrin GAMs without cationic polymer led to variable results. Animals that received rhBMP2 protein showed increased bone volume, and osseous unions were achieved in two of six animals.

conclusionsCationic polymers decrease therapeutic efficiency of fibrin GAM-based BMP2/7 plasmid codelivery in bone regeneration. Nonviral gene transfer of BMP2/7 plasmids needs alternative promoters (e.g. by sonoporation, electroporation) to produce beneficial clinical effects.

Indexed as

AnimalsBone Morphogenetic Protein 2Bone Morphogenetic ProteinsBone RegenerationDisease Models, AnimalFibrinGenetic TherapyGene Transfer TechniquesMaleOsteogenesisPlasmidsRats, Sprague-DawleyRecombinant ProteinsTissue EngineeringTransforming Growth Factor betaBmp2 protein, ratBone Morphogenetic Protein 2Bone Morphogenetic ProteinsFibrinrecombinant human bone morphogenetic protein-2Recombinant ProteinsTransforming Growth Factor beta

Identifiers

PMID25192687
OpenAlexW2168748728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.